Success Metrics

Clinical Success Rate
81.8%

Based on 9 completed trials

Completion Rate
82%(9/11)
Active Trials
0(0%)
Results Posted
33%(3 trials)
Terminated
2(17%)

Phase Distribution

Ph not_applicable
1
8%
Ph phase_2
2
17%
Ph phase_4
9
75%

Phase Distribution

0

Early Stage

2

Mid Stage

9

Late Stage

Phase Distribution12 total trials
Phase 2Efficacy & side effects
2(16.7%)
Phase 4Post-market surveillance
9(75.0%)
N/ANon-phased studies
1(8.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

81.8%

9 of 11 finished

Non-Completion Rate

18.2%

2 ended early

Currently Active

0

trials recruiting

Total Trials

12

all time

Status Distribution
Completed(9)
Terminated(2)
Other(1)

Detailed Status

Completed9
Terminated2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
0
Success Rate
81.8%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (16.7%)
Phase 49 (75.0%)
N/A1 (8.3%)

Trials by Status

terminated217%
unknown18%
completed975%

Recent Activity

0 active trials
Showing 5 of 12
terminatedphase_2

Effect of Topical Nepafenac in Macular Thickening Related to Pan-retinal Photocoagulation

NCT00801905
terminatedphase_4

Macular Edema Nepafenac vs. Difluprednate Uveitis Trial

NCT01939691
completedphase_4

Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1%

NCT01310127
completedphase_4

Study Title: Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (Nepafenac Ophthalmic Suspension) 0.3% QD With Extra (Pulse) Dose on Day of Surgery for Treatment of Ocular Inflammation Associated With Cataract Surgery in a Randomized, Single Masked Clinical Trial

NCT03886779
unknownnot_applicable

Comparison of Diclofenac vs. Nepafenac Ophthalmic Drops: Patient Comfort

NCT02506348
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT00801905Phase 2

Effect of Topical Nepafenac in Macular Thickening Related to Pan-retinal Photocoagulation

Terminated
NCT01939691Phase 4

Macular Edema Nepafenac vs. Difluprednate Uveitis Trial

Terminated
NCT01310127Phase 4

Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1%

Completed
NCT03886779Phase 4

Study Title: Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (Nepafenac Ophthalmic Suspension) 0.3% QD With Extra (Pulse) Dose on Day of Surgery for Treatment of Ocular Inflammation Associated With Cataract Surgery in a Randomized, Single Masked Clinical Trial

Completed
NCT02506348Not Applicable

Comparison of Diclofenac vs. Nepafenac Ophthalmic Drops: Patient Comfort

Unknown
NCT00900887Phase 2

Topic Antiinflammatory Therapy Added to Selective Photocoagulation in Macular Edema

Completed
NCT02084576Phase 4

Anti-inflammatory Efficacy for Prophylaxis of Cystoid Macular Edema (CME) After Phacoemulsification

Completed
NCT01995890Phase 4

Effect of Nepafenac Eye Drops on Intraocular Pressure in Normal Eyes

Completed
NCT01021761Phase 4

A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification

Completed
NCT00494494Phase 4

Effect of Nepafenac on Post-operative Macular Swelling Following Uncomplicated Cataract Surgery

Completed
NCT00377546Phase 4

Comparison of Vitreous Levels of Acular LS 0.04%, Xibrom 0.09%, and Nevanac 0.1%

Completed
NCT00407017Phase 4

Therapeutic Variables in Cataract Surgery

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12